New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export MRK’s income statement to Excel — free account
Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
134.95
2.21
+1.66%
Follow MRK
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $28.02 was left as profit. Gross margin has fallen two quarters running, from 74.2% to 72.9%. What is an income statement?
| Revenue | 18.1 | 100.0% |
|---|---|---|
| Cost of revenue | −4.9 | −27.1% |
| Gross profit | 13.2 | 72.9% |
| Research & development | −4.5 | −25.1% |
| Selling, general & admin | −2.9 | −16.0% |
| Operating income | 5.8 | 31.9% |
| Other income, net | −0.2 | −1.2% |
| Income tax | −0.5 | −2.7% |
| Net income | 5.1 | 28.0% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $16.4B | $16.3B | $16.6B | $18.1B |
| Operating income | $4.1B | −$3.2B | −$433M | $5.8B |
| Net income | $3.0B | −$4.2B | −$1.3B | $5.1B |
| Net margin (right axis) | 18.1% | −26.1% | −8.1% | 28.0% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
18,085.00 | 16,607.00 | 16,286.00 | 16,400.00 |
+8 more quarters Free account |
Revenue Growth |
4.68% | 5.07% | 4.87% | 4.97% | |
Cost of Revenue |
4,892.00 | 4,395.00 | 4,195.00 | 5,551.00 | |
Gross Profit |
13,193.00 | 12,212.00 | 12,091.00 | 10,849.00 | |
R&D Expenses |
4,537.00 | 9,741.00 | 12,592.00 | 3,886.00 | |
SG&A Expenses |
2,886.00 | 2,904.00 | 2,700.00 | 2,899.00 | |
Operating Income |
5,770.00 | (433.00) | (3,201.00) | 4,064.00 | |
Non-operating Income/Expense |
(211.00) | (250.00) | (333.00) | (644.00) | |
| 5,559.00 | (683.00) | (3,534.00) | 3,420.00 | ||
Income Tax Provision |
492.00 | 654.00 | 709.00 | 457.00 | |
Income after Tax |
5,067.00 | (1,337.00) | (4,243.00) | 2,963.00 | |
Non-Controlling Interest |
2.00 | (2.00) | (3.00) | (1.00) | |
Net Income Common |
5,065.00 | (1,335.00) | (4,240.00) | 2,963.00 | |
EPS (Basic) |
2.04 | (0.54) | (1.72) | 1.19 | |
EPS (Diluted) |
2.04 | (0.54) | (1.72) | 1.19 | |
Shares (Basic, Weighted) |
2,468.00 | 2,470.00 | 2,472.00 | 2,502.00 | |
Shares (Diluted, Weighted) |
2,478.00 | 2,470.00 | 2,472.00 | 2,507.00 | |
Gross Margin |
72.95% | 73.54% | 74.24% | 66.15% | |
EBIT Margin |
31.90% | (2.61%) | (19.65%) | 24.78% | |
EBT margin |
30.74% | (4.11%) | (21.70%) | 20.85% | |
Net Profit Margin |
28.01% | (8.04%) | (26.03%) | 18.07% | |
EBITDA |
7,553.00 | 1,150.00 | (1,689.00) | 6,530.00 | |
EBIT |
5,770.00 | (433.00) | (3,201.00) | 4,064.00 | |
Income from Continuous Operations |
5,067.00 | (1,337.00) | (4,243.00) | 2,963.00 | |
Consolidated Net Income/Loss |
5,067.00 | (1,337.00) | (4,243.00) | 2,963.00 | |
EPS (Basic, from Continuous Ops) |
2.05 | (0.54) | (1.72) | 1.20 | |
EPS (Diluted, from Cont. Ops) |
2.04 | (0.54) | (1.72) | 1.20 | |
EPS (Basic, Consolidated) |
2.05 | (0.54) | (1.72) | 1.20 | |
EPS (Diluted, Consolidated) |
2.04 | (0.54) | (1.72) | 1.20 | |
Shares (Diluted, Average) |
2,478.00 | 2,470.00 | 2,472.00 | 2,488.00 | |
EBITDA Margin |
41.76% | 6.92% | (10.37%) | 39.82% | |
Operating Cash Flow Margin |
36.26% | 32.34% | 24.06% | 17.42% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026